Key Highlights
- Neffy U.S. net product revenue was $17.5 million in the first quarter of 2026, within total revenue of $22.7 million, versus $8.0 million total a year earlier.
- ARS Pharma disclosed on June 24, 2026 that no new commercial formulary additions or coverage decisions were issued for neffy in the July 1, 2026 cycle, following a CVS Caremark proposal it had described as in final-stage review.
- The company lowered its planned full-year 2026 cash-based operating expenses (excluding cost of goods sold) to approximately $248 million and reaffirmed a path to cash-flow breakeven in 2027.
- Cash, cash equivalents and short-term investments stood at $201.0 million as of March 31, 2026, which management says covers at least the next 12 months of needs.
ARS (NASDAQ:SPRY) Pharmaceuticals is scaling U.S. sales of neffy, the first needle-free epinephrine nasal spray, even after CVS Caremark did not add the product to its commercial formulary for the July 1, 2026 cycle. First-quarter 2026 net product revenue reached $17.5 million, pediatric access has widened, and global partners are extending the franchise abroad, but heavy losses and unresolved payer economics still cloud the path to breakeven.
A Needle-Free Product Facing a Payer Bottleneck
ARS Pharmaceuticals, Inc. (SPRY) has spent the past two years trying to convert a genuine product breakthrough, the first and only FDA-approved needle-free epinephrine treatment, into a durable commercial franchise. Neffy, an intranasal spray for Type I allergic reactions including anaphylaxis, has posted accelerating prescription volume since launch, and the San Diego-based company says demand has kept growing even without additional insurer wins. That resilience is now being tested by a stalled negotiation with CVS Caremark, a major pharmacy benefit manager.
In its May 15, 2026 release, ARS Pharma said a proposal to add neffy to CVS Caremark's formulary without prior authorization, targeting a July 1, 2026 effective date, was in the final stages of CVS's approval process, with economics consistent with its roughly 50% gross-to-net retention target. Six weeks later, its June 24, 2026 update reported that no new formulary additions or coverage decisions had been issued for neffy in the July 1 cycle, despite payer discussions continuing into mid-June. ARS Pharma framed this as ongoing rather than a rejection, saying it intends to keep working with remaining payers, and that neffy remains accessible through existing coverage plus a new retail cash option priced consistent with other epinephrine products. The company did not attribute a reason to CVS.
From Merger Shell to Single-Product Commercial Company
ARS Pharma traces its public listing to a November 2022 merger with Silverback Therapeutics, Inc., but its story is built around neffy, indicated in the U.S. for those weighing 33 pounds or more and sold in Europe as EURneffy. ARS Pharma expanded its sales force from 106 to 148 representatives in the first quarter of 2026, and more than 28,000 healthcare providers had prescribed neffy by the May 2026 release, roughly half of them repeat prescribers.
Catalyst Analysis: ARS Pharmaceuticals (SPRY) Navigates a Payer Standoff
The CVS Caremark episode is the clearest near-term catalyst for ARS Pharmaceuticals (SPRY): gross-to-net economics, not prescription counts alone, determine how much of neffy's volume converts into revenue. Until a major PBM formalizes access, more prescriptions likely rely on existing coverage, a $0 co-pay program, and a point-of-sale cash option, introduced in May 2026, that converts a rejected claim to a $199 price.
Payer dynamics are improving elsewhere. State Medicaid coverage had expanded to nine unrestricted-formulary plans as of the Q1 2026 release, most recently Florida, effective July 1, 2026. The FDA's late-March 2026 approval removing the age-based dosing criterion from the neffy 1 mg label also widened pediatric eligibility. Investors are watching whether renewed CVS talks, Medicaid gains, and renewals as early fills expire can offset the absence of a big-PBM formalization.
First-Quarter 2026 Performance: Growth Continues, Losses Widen
For the three months ended March 31, 2026, ARS Pharma reported total revenue of $22.7 million: $17.5 million in U.S. neffy net product revenue, $2.5 million in collaboration revenue and $2.7 million in supply revenue, versus $8.0 million total a year earlier. The collaboration figure included a $2.5 million portion of a $5.0 million ALK milestone tied to the EU approval of neffy 1 mg.
Operating expenses rose with the commercial build-out: cost of goods sold was $6.3 million, R&D was $4.3 million, and SG&A was $72.2 million, up from $41.1 million a year earlier, producing a net loss of $60.6 million, or $0.61 per share, versus a $33.9 million loss, or $0.35 per share, a year earlier.
Revenue, Cash and the Path to Breakeven
ARS Pharma ended the quarter with $201.0 million in cash, equivalents and short-term investments, down from $245.0 million at December 31, 2025, which its 10-Q states is sufficient for at least the next 12 months. The balance sheet also carries $96.5 million of term loans, net, a $74.7 million ALK-related financing liability, and $48.3 million of accounts payable and accrued liabilities, including $15.4 million of accrued gross-to-net rebates.
The June 24, 2026 update lowered planned 2026 cash-based operating expenses, excluding cost of goods sold, to approximately $248 million, and reaffirmed a path to cash-flow breakeven in 2027, a target repeated since the fourth-quarter 2025 release, when full-year 2025 product revenue totaled $72.2 million against a net loss of $171.3 million.
Pediatric Reach, Global Partnerships and the CSU Pipeline
The neffyinSchools program had reached more than 10,000 schools by mid-2026, with over 200 reported successful uses. Internationally, ALK-Abelló is ARS Pharma's principal partner outside the U.S., Japan, Greater China, Australia and New Zealand under a November 2024 agreement including a $145.0 million upfront payment and up to $300.0 million in further sales milestones. ALK secured EU authorization for EURneffy 1 mg in patients aged four and older, effective March 31, 2026, and Health Canada approved neffy in April 2026 ahead of an ALK-led launch. Pediatrix Therapeutics and Seqirus hold China and Australia/New Zealand rights, respectively. A Phase 2b trial in chronic spontaneous urticaria, estimated to affect roughly 1.6 million U.S. patients, completed interim enrollment, with data due in the fourth quarter of 2026.
Material Risks Facing ARS Pharma's Single-Product Model
ARS Pharma's fortunes remain concentrated in one product, so gross-to-net retention could fall below its 50% target if payer access is delayed further. A July 7, 2026 leadership transition (co-founder CEO Richard Lowenthal departing and President Donn Casale becoming CEO) adds uncertainty. Heavy losses, a $355.2 million accumulated deficit and $96.5 million of secured term debt add leverage risk if breakeven slips beyond 2027, and the early-stage CSU program's data could disappoint.
Outlook
The upside case rests on prescription growth outpacing payer friction, CVS Caremark talks eventually formalizing access, expanding Medicaid coverage, and early prescribers renewing, layered on milestone income as ALK, Pediatrix and Seqirus territories scale. A base case sees the company hit its reduced $248 million 2026 opex plan and approach 2027 breakeven on the timeline management has reiterated. A downside scenario involves the CVS proposal stalling, slower Medicaid conversion, a bumpy CEO transition, or disappointing CSU data, any of which could push breakeven further out.
Conclusion
ARS Pharmaceuticals, Inc. (SPRY) enters the second half of 2026 with commercial momentum behind neffy, verified first-quarter revenue growth, a global partner network anchored by ALK-Abelló, and a lower operating-expense plan aimed at 2027 cash-flow breakeven. Whether SPRY can convert that momentum into a redefined allergy-care market depends on resolving the CVS Caremark standoff and other payer negotiations the company has disclosed remain unresolved.
This article is for informational purposes only and does not constitute investment advice or a recommendation to buy, sell, or hold any security. Share prices can rise or fall, and past performance does not guarantee future results. Investors should conduct independent research and consult a licensed financial adviser before making investment decisions.
_11_16_2026_14_38_45_453029.jpg)





Please wait processing your request...